Search

Search Constraints

You searched for: Author/Creator McConkey, David

Search Results

2. 506 The tumor immune microenvironment of metastatic osteosarcoma is marked by lymphocyte exclusion and impacts patient progression-free survival. (10th December 2020)

3. 506 The tumor immune microenvironment of metastatic osteosarcoma is marked by lymphocyte exclusion and impacts patient progression-free survival. (9th November 2020)

4. BCG invokes superior STING‐mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. Issue 2 (10th December 2021)

5. Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. (4th May 2019)

6. PD53-01 MOLECULAR SUBTYPING OF N-METHYL-N-NITROSOUREA (MNU) RAT MODEL OF UROTHELIAL CARCINOMA REVEALS BOTH LUMINAL AND BASAL SIGNATURES. (May 2022)

9. Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome. Issue 2 (February 2021)

10. PD53-11 DIVERGENT THERAPEUTIC OUTCOMES OF STING AGONIST ADU-S100 IN INTRATUMORAL AND INTRAVESICAL TREATMENT REGIMENS IN SYNGENEIC MURINE MB49 AND IN THE N-METHYL-N-NITROSOUREA (MNU) RAT MODEL OF UROTHELIAL CARCINOMA. (May 2022)